SLGL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	15 208.00
Średni wolumen	30 420.00
Kapitalizacja rynkowa	23.69M
EPS	$0 ( 2024-03-15 )
Następna data zysków	( $-0.150 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.0420 (4.94%)

Sol Gel Technologies Ltd Korelacja

10 Najbardziej pozytywne korelacje
SIRI	0.864
CARE	0.862
FXNC	0.856
CFB	0.849
SFST	0.839
NFBK	0.839
HAIN	0.838
ACLS	0.836
OTEX	0.831
TTEC	0.829

10 Najbardziej negatywne korelacje
FRLA	-0.832
INCR	-0.832
VITL	-0.826
VTVT	-0.826
IXAQ	-0.819
TRMR	-0.818
TWLVU	-0.813
KNTK	-0.811
RIVE	-0.809
PWP	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sol Gel Technologies Ltd Finanse

Annual	2023
Przychody:	$1.55M
Zysk brutto:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2023
Przychody:	$1.55M
Zysk brutto:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2022
Przychody:	$3.88M
Zysk brutto:	$-8.80M (-226.60 %)
EPS:	$-0.590

FY	2021
Przychody:	$31.27M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$0.140

Financial Reports:

No articles found.

Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.